伏立康唑治疗播散性马尔尼菲蓝状菌病临床分析

中国真菌学杂志　 2017, Vol. 12 　Issue (2): 92-97.

伏立康唑治疗播散性马尔尼菲蓝状菌病临床分析

魏金瑛¹, 欧阳沿音², 蔡双启³, 梁浩⁴, 曹存巍¹

1. 广西医科大学第一附属医院皮肤性病科广西艾滋病防治研究重点实验室, 南宁 530021;
2. 广西壮族自治区皮肤病医院, 南宁 530003;
3. 广西医科大学第一附属医院呼吸疾病研究所, 南宁 530021;
4. 广西医科大学公共卫生学院 & 生命科学研究院, 南宁 530021

收稿日期:2016-12-08 出版日期:2017-04-28 发布日期:2017-04-28
通讯作者: 曹存巍,E-mail:caocunwei@yeah.net E-mail:caocunwei@yeah.net
作者简介:魏金瑛,女(汉族),硕士研究生在读.E-mail:13807725746@163.com
基金资助:
国家自然科学基金（81571971，81271804）

Administration of voriconazole in disseminated penicilliosis marneffei: a retrospective study

WEI Jin-ying¹, OUYANG Yan-yin², CAI Shuang-qi³, LIANG Hao⁴, CAO Cun-wei¹

1. Department of Dermatology and Venereology, The First Affiliated hospital of Guangxi Medical University, Guangxi Key Laboratory of AIDS Prevention and Treatment, Nanning 530021, China;
2. Department of Dermatology, Guangxi Institute of Dermatology, Nanning 530003, China;
3. Department of Respiratory, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China;
4. Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health & Life Sciences Institute, Guangxi Medical University, Nanning 530021, China

Received:2016-12-08 Online:2017-04-28 Published:2017-04-28

摘要/Abstract

摘要：

目的采用回顾性分析的方法探讨伏立康唑治疗播散性马尔尼菲蓝状菌病（PSM）的临床疗效及安全性。方法收集2010年1月~2015年6月期间，诊断为PSM且使用伏立康唑作为初始抗真菌治疗的患者资料。伏立康唑近期疗效及安全性分别于治疗16周或治疗结束时予以评估，远期疗效及安全性则于治疗结束后6个月，12个月后予以评估。结果共有17例患者采用伏立康唑进行初始治疗，3例患者未能完成疗程，在完成治疗的14例患者中，10例病情得到完全控制，3例部分控制，1例无效。在治疗结束6个月后随访的11例患者中，8例治愈，3例复发；治疗结束12月后访视的8例患者病情均无复发。所有患者在治疗期间及治疗结束后均未发生明显的毒副作用。结论提示伏立康唑治疗播散性PSM具有较好的近期及远期临床疗效及安全性，可作为PSM治疗的一种新方法。

关键词: 伏立康唑, 马尔尼菲蓝状菌病, 疗效, 安全性

Abstract:

Objective The aim of this retrospective study is to evaluate the efficacy and safety of voriconazole in the treatment of Penicilliosis marneffei (PSM)patients with or without HIV infection in clinical setting.Methods The disseminated PSM patients who received intravenous voriconazole (6 mg/kg every 12 hours for the first 24 hours and then 4 mg/kg every 12 hours afterwards) as primary antifungal treatment were enrolled.The following duration of antifungal treatment varied at the discretion of investigators according to the response of the patients.Primary response was evaluated at Week 16 or at the end of treatment (EOT).Follow-up evaluations were performed at 6 months and 1 year after EOT.Results A total of seventeen patients enrolled in this study, three patients were not evaluable because the treatment discontinued prematurely.Among the remaining fourteen patients, thirteen had satisfied response to treatment, ten patients had complete response and three patients had partial response at Week 16.Only one patient was evaluated as failure.Follow-up assessments in eleven patients showed eight patients were cured and the remaining three patients relapsed at 6 months after EOT.Eight patients were assessed 1 year later, none of them relapsed.No adverse events associated to voriconazole were recorded during the treatment.Conclusion The results from our study suggest that voriconazole is an effective, well-tolerated therapeutic option for disseminated P.marneffei infection.

Key words: voriconazole, disseminated penicilliosis marneffei, efficacy, safety

中图分类号:

R519.8

魏金瑛, 欧阳沿音, 蔡双启, 梁浩, 曹存巍. 伏立康唑治疗播散性马尔尼菲蓝状菌病临床分析[J]. 中国真菌学杂志, 2017, 12(2): 92-97.

WEI Jin-ying, OUYANG Yan-yin, CAI Shuang-qi, LIANG Hao, CAO Cun-wei. Administration of voriconazole in disseminated penicilliosis marneffei: a retrospective study[J]. Chinese Journal of Mycology, 2017, 12(2): 92-97.

参考文献

[1] Ustianowski AP,Sieu TP,Day JN.Penicillium marneffei infection in HIV[J].Curr Opin Infect Dis,2008,21(1):31-36.
[2] 赵国庆,冉玉平,向耘.中国大陆马尔尼菲青霉病的临床表现及流行病学特征的系统评价[J].中国真菌学杂志,2007,2(2):68-72.
[3] Deng Z,Ribas JL,Gibson DW,et al.Infections caused by Penicillium marneffei in China and Southeast Asia:review of eighteen published cases and report of four more Chinese cases[J].Rev Infect Dis,1988,10(3):640-652.
[4] Kawila R,Chaiwarith R,Supparatpinyo K.Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand:a retrospective study[J].BMC Infect Dis,2013,13(1):464-468.
[5] Duong TA.Infection due to Penicillium marneffei,an emerging pathogen:review of 155 reported cases[J].Clin Infect Dis,1996,23(1):125-130.
[6] Vanittanakom N,Sirisanthana T.Penicillium marneffei infection in patients infected with human immunodeficiency virus[J].Curr Top Med Mycol,1997,8(1-2):35-42.
[7] Xi L,Lu C,Zhou X,et al.Fifteen cases of penicilliosis in Guangdong,China[J].Mycopathologia,2004,158(2):151-155.
[8] Sirisanthana T,Nelson KE.Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in Human Immunodeficiency Virus-infected patients[J].Clin Infect Dis,1998,26(5):1107-1110.
[9] Walsh TJ,Pappas P,Winston DJ,et al.Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever[J].N Engl J Med,2002,346(4):225-234.
[10] Zmeili OS,Soubani AO.Pulmonary aspergillosis:a clinical update[J].QJM,2007,100(6):317-334.
[11] Greer ND.Voriconazole:the newest triazole antifungal agent[J].Proc,2003,16(2):241-248.
[12] Guideline for prevention and treatment of opportunistic infections in HIV-infected adults and adolescent[EB/OL].(2005-12-12)http://aidsinfo.nih.gov/guidelines on 12/12/2015.
[13] Liu D,Liang L,Chen J.In vitro antifungal drug susceptibilities of Penicillium marneffei,from China[J].J Infect Chemother,2013,19(4):776-778.
[14] Mo D,Li X,Wei L,et al.In vitro interactions of calcineurin inhibitors with conventional antifungal agents against the yeast form of Penicillium marneffei[J].Mycopathologia,2014,178(3):217-220.
[15] Doby EH,Jr BD,Blaschke AJ,et al.Therapeutic monitoring of voriconazole in children less than 3 years of age:a case report and summary of voriconazole concentrations for 10 children[J].Pediatr Infect Dis J,2012,31(6):632-635.
[16] Döring M,Eikemeier M,Cabanillas Stanchi KM,et al.Antifungal prophylaxis with posaconazole vs.fluconazole or itraconazole in pediatric patients with neutropenia[J].Eur J Clin Microbiol Infect Dis,2015,34(6):1189-1200.
[17] Espinel-Ingroff A,Boyle K,Sheehan DJ.In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods:review of the literature[J].Mycopathologia,2001,150(3):101-115.
[18] 李梦,廖万清.侵袭性真菌感染治疗新进展[J].中国真菌学杂志,2012,7(1):47-51.
[19] Perfect JR,Marr KA,Walsh TJ,et al.Voriconazole treatment for less-common,emerging,or refractory fungal infections[J].CID,2003,36(9):1122-1131.
[20] Supparatpinyo K,Schlamm HT.Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients[J].Am J Trop Med Hyg,2007,77(2):350-353.
[21] Supparatpinyo K,Nelson KE,Merz WG,et al.Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens[J].Antimicrob Agents Chemother,1993,37(11):2407-2411.